EP
PASG icon

Eversept Partners’s Passage Bio PASG Stock Holding History

Eversept Partners’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-131,581
Closed -$1.03M – 140
2026
Q1 		$1.03M Buy
131,581
+5,351
+4% +$55.4K 0.05% 108
2025
Q4 		$1.49M Buy
+126,230
New +$1.09M 0.08% 95

Other funds holding PASG

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $291M AUM 19.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VA
Verdad Advisers Boston, Massachusetts $104M AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Eversept Partners's PASG Position: Q2 2026 in Review

Eversept Partners sold out of Passage Bio (PASG) in Q2 2026, closing a stake of 131,581 shares — an estimated $1.03M sold.

Eversept Partners first reported a position in PASG in Q4 2025 and held it in 2 quarters. The position peaked at $1.49M in Q4 2025. 29 funds tracked by Wall St. Rank hold PASG as of Q2 2026.

  • Eversept Partners reported no remaining Passage Bio position as of Q2 2026 after selling out during the quarter.
  • Eversept Partners sold 131,581 Passage Bio shares in Q2 2026, an estimated $1.03M.
  • Eversept Partners first reported a position in Passage Bio in Q4 2025 and held it in 2 quarters.
  • Eversept Partners's Passage Bio position peaked at $1.49M in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Passage Bio as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.